RESUMO
Since it is recognized that acute inflammation of the temporomandibular joint results in sleep disturbances in male rats, and that the orofacial region may display a site-specific effect of ovarian hormones on nociception, we hypothesized that distinct genders would respond differently when subjected to this inflammatory acute orofacial pain. Sleep was monitored after injection of saline/Freund's adjuvant into the temporomandibular joint in male and female (proestrus and diestrus phases) rats. Progesterone and stress-related hormones were also assessed. In males, Freund's adjuvant induced a significant nociceptive response and sleep disturbances. Behavior and sleep architecture in the females remained unaffected. Our results suggest that females and males present distinct responses to an acute model of orofacial pain.
Assuntos
Artrite/complicações , Modelos Animais de Doenças , Transtornos do Sono-Vigília/etiologia , Sono/fisiologia , Transtornos da Articulação Temporomandibular/complicações , Adjuvantes Imunológicos , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/fisiologia , Animais , Nível de Alerta/fisiologia , Artrite/fisiopatologia , Diestro/fisiologia , Ingestão de Líquidos/fisiologia , Ingestão de Alimentos/fisiologia , Eletroencefalografia , Eletromiografia , Feminino , Adjuvante de Freund , Masculino , Dor/fisiopatologia , Proestro/fisiologia , Progesterona/sangue , Progesterona/fisiologia , Progestinas/sangue , Progestinas/fisiologia , Distribuição Aleatória , Ratos , Ratos Wistar , Fatores Sexuais , Fases do Sono/fisiologia , Cloreto de Sódio , Transtornos da Articulação Temporomandibular/fisiopatologia , Vigília/fisiologiaRESUMO
Since it is recognized that cyclo-oxygenase-2 mediates nociception and the sleep-wake cycle as well, and that acute inflammation of the temporomandibular joint (TMJ) results in sleep disturbances, we hypothesized that cyclo-oxygenase-2 inhibitor would restore the sleep pattern in this inflammatory rat model. First, sleep was monitored after the injection of Freund's adjuvant (FA group) or saline (SHAM group) into the rats' temporomandibular joint. Second, etoricoxib was co-administered in these groups. The Freund's adjuvant group showed a reduction in sleep efficiency, in rapid eye movement (REM), and in non-REM sleep, and an increase in sleep and REM sleep latency when compared with the SHAM group, while etoricoxib substantially increased sleep quality in the Freund's adjuvant group. These parameters returned progressively to those found in the SHAM group. Etoricoxib improved the sleep parameters, suggesting the involvement of the cyclo-oxygenase-2 enzyme in acute inflammation of the TMJ, specifically in REM sleep.
Assuntos
Artrite Experimental/tratamento farmacológico , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Ciclo-Oxigenase 2/fisiologia , Piridinas/uso terapêutico , Transtornos do Sono-Vigília/tratamento farmacológico , Sulfonas/uso terapêutico , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Transtornos da Articulação Temporomandibular/enzimologia , Doença Aguda , Animais , Artrite Experimental/complicações , Artrite Experimental/enzimologia , Inibidores de Ciclo-Oxigenase 2/farmacologia , Etoricoxib , Masculino , Prostaglandina D2/antagonistas & inibidores , Prostaglandina D2/metabolismo , Distribuição Aleatória , Ratos , Ratos Wistar , Transtornos do Sono-Vigília/enzimologia , Transtornos do Sono-Vigília/etiologia , Sono REM/fisiologiaRESUMO
Since nitric oxide is related to nociception and the sleep-wake cycle, this study sought to determine its involvement in the altered sleep pattern in a temporomandibular joint pain model by investigating the effect of the inhibitor of nitric oxide synthase (L-NAME) and that of its precursor (L-arginine). The temporomandibular joints of test animals were injected with Freund's adjuvant or saline, and their sleep was recorded. The procedure was repeated after the administration of L-NAME and L-arginine. L-NAME increased rapid eye movement (REM) sleep in the control group. The orofacial pain group showed a reduction in total sleep time and an increase in sleep latency compared with the SHAM group. L-NAME increased sleep time, non-rapid eye movement (NREM), and REM sleep and reduced sleep latency in the orofacial pain group. L-arginine did not alter sleep parameters. Thus, L-NAME improved sleep efficiency, whereas L-arginine did not modify it, suggesting the involvement of nitric oxide in painful temporomandibular joint conditions.
Assuntos
Dor Facial/complicações , Óxido Nítrico/fisiologia , Transtornos do Sono-Vigília/etiologia , Transtornos da Articulação Temporomandibular/complicações , Animais , Arginina/uso terapêutico , Artrite Experimental/complicações , Modelos Animais de Doenças , Inibidores Enzimáticos/uso terapêutico , Masculino , NG-Nitroarginina Metil Éster/uso terapêutico , Doadores de Óxido Nítrico/uso terapêutico , Óxido Nítrico Sintase/antagonistas & inibidores , Distribuição Aleatória , Ratos , Ratos Wistar , Fases do Sono/efeitos dos fármacos , Sono REM/efeitos dos fármacos , Fatores de TempoRESUMO
This study sought to assess sleep patterns in rats injected with Freund's adjuvant (FA) in the temporomandibular joint (TMJ) as a potential experimental orofacial pain model. Pain response to indomethacin was also assessed. Rats were implanted with electrodes to record electrocorticogram and eletromyogram signals. After a baseline (B) recording, they were injected with Freund's adjuvant (orofacial pain group, n=8) or saline (sham group, n=8) in the temporomandibular joint, and their sleep was monitored over two 12-h light periods. In the second phase of the study, after injecting Freund's adjuvant, indomethacin was administered (1 mg/kg p.o.) at 12- intervals, and sleep patterns were recorded for two additional light periods. The orofacial pain group showed a reduction in sleep efficiency during the two light periods compared with the baseline recording and with the sham group (p<0.001). Increases in sleep and paradoxical sleep (PS) latencies of approximately 200% and 420%, respectively, were observed, as well as an increase in the number of awakenings during both periods (p<0.001). Treatment with indomethacin increased sleep efficiency (p<0.001) and paradoxical sleep time (p<0.001). The number of awakenings (p<0.001) and sleep (p<0.001) and paradoxical sleep latencies (p<0.001) were reduced reestablishing the normal sleep pattern. The results showed the reliability and usefulness of the temporomandibular joint pain model to characterize sleep disturbances related to pain and its response to indomethacin.